-
-
-
-
-
-
-
Teva Pharma (TEVA) PT Raised to $42 at UBS
-
-
-
-
-
-
-
Teva Pharma (TEVA) Tops Q3 EPS by 10c, Offers Guidance
-
-
-
-
-
-
-
Teva Pharma (TEVA) Tops Q1 EPS by 4c; offers guidance
-
-
-
-
-
-
-
Teva Pharm to launch Humira biosimilar as Q1 profit misses estimates
-
-
-
-
-
-
-
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
-
-
-
-
-
-
-
Teva Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance
-
-
-
-
-
-
-
Teva Reports Second Quarter 2023 Financial Results
-
1,216,208 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

